ストックスクリーナーアプリを入手
3.00
1.69%
0.05
アフターアワーズ：
3.01
0.010
+0.33%
前日終値:
$2.95
開ける：
$2.96
24時間の取引高:
104.99K
Relative Volume:
0.58
時価総額：
$180.24M
収益：
-
当期純損益:
$-52.37M
株価収益率:
-2.6316
EPS:
-1.14
ネットキャッシュフロー:
$-43.09M
1週間 パフォーマンス:
+3.27%
1か月 パフォーマンス:
+26.58%
6か月 パフォーマンス:
-14.04%
1年 パフォーマンス:
+36.99%
1日の値動き範囲:
$2.95
$3.02
1週間の範囲:
$2.79
$3.14
52週間の値動き範囲:
$1.8101
$5.09
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
名前
Acumen Pharmaceuticals Inc
セクター
電話
925-368-8508
住所
427 PARK ST., CHARLOTTESVILLE
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-26 | 開始されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-07-20 | 再開されました | BofA Securities | Buy |
| 2023-05-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-07-15 | 開始されました | BTIG Research | Buy |
| 2022-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-21 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-07-26 | 開始されました | BofA Securities | Neutral |
| 2021-07-26 | 開始されました | Credit Suisse | Outperform |
| 2021-07-26 | 開始されました | Stifel | Buy |
| 2021-07-26 | 開始されました | UBS | Buy |
すべてを表示
Acumen Pharmaceuticals Inc (ABOS) 最新ニュース
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 - The Manila Times
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference - The Manila Times
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference - StockTitan
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Significant Decrease in Short Interest - MarketBeat
National Bank Financial Forecasts TSE:BIP Q3 Earnings - Defense World
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 18.6% in October - Defense World
Acumen reveals Alzheimer's trial screening method By Investing.com - Investing.com Australia
Halozyme to Report Third Quarter 2024 Financial and Operating Results - The Malaysian Reserve
Acumen reveals Alzheimer's trial screening method - Investing.com India
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference - The Manila Times
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on - The Bakersfield Californian
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
3 US Penny Stocks With Market Caps Under $500M To Consider - Simply Wall St
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Decreases By 7.7% - MarketBeat
Lucy Therapeutics Appoints Kim Drapkin as Board Chair - BioSpace
Millennium Management LLC Has $4.87 Million Position in Exponent, Inc. (NASDAQ:EXPO) - Defense World
Millennium Management LLC Makes New Investment in Super Hi International Holding Ltd. (NASDAQ:HDL) - Defense World
Millennium Management LLC Has $4.88 Million Stock Position in Alamo Group Inc. (NYSE:ALG) - Defense World
Millennium Management LLC Cuts Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - MarketBeat
Central Nervous System (CNS) Biomarkers Market Expected - openPR
Renaissance Technologies LLC Acquires Shares of 338,100 Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - MarketBeat
Acumen Pharmaceuticals (ABOS) Price Target Increased by 6.67% to 13.06 - MSN
MGO Private Wealth LLC Buys 9,590 Shares of NVIDIA Co. (NASDAQ:NVDA) - Defense World
Sei Investments Co. Makes New $2.49 Million Investment in Plains GP Holdings, L.P. (NYSE:PAGP) - Defense World
Stifel maintains Buy rating on Acumen Pharma shares - Investing.com India
Park National Corp OH Boosts Stake in Vanguard High Dividend Yield ETF (NYSEARCA:VYM) - Defense World
Acumen Pharma retains stock target with Buy rating on AD drug potential - Investing.com India
Analysts’ Updated EPS Estimates for October 3rd (ABOS, AIOT, AMZN, ATLX, BCTX, BIGC, BITF, BTDR, CAG, CALX) - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Given "Buy" Rating at HC Wainwright - MarketBeat
Acumen Pharma retains stock target with Buy rating on AD drug potential By Investing.com - Investing.com South Africa
Acumen and Lonza expand collaboration for early Alzheimer's drug - European Pharmaceutical Manufacturer
AQR Capital Management LLC Purchases 32,785 Shares of Otis Worldwide Co. (NYSE:OTIS) - Defense World
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Sunbelt Securities Inc. - Defense World
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference - ForexTV.com
Valmet Oyj (VLMTY) To Go Ex-Dividend on October 1st - Defense World
Comprehensive Analysis of Growth Drivers and Challenges in the Neurological Biomarkers Market In New Report - WhaTech
ABOSAcumen Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Verona Pharma plc (VRP.L) (LON:VRP) Shares Pass Above 200 Day Moving Average of $55.00 - Defense World
First Trust Nasdaq Transportation ETF (NASDAQ:FTXR) Announces Quarterly Dividend of $0.13 - Defense World
Acumen extends Alzheimer's drug partnership with Lonza By Investing.com - Investing.com Australia
Acumen extends Alzheimer's drug partnership with Lonza - Investing.com India
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer's Disease - The Manila Times
Acumen extends collaboration with Lonza - TipRanks
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease - StockTitan
Acumen Health Holdings to Acquire Avenova Brand Enhancing Eye Health Portfolio - MSN
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 - EIN News
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - PR Newswire
Evergreen With Envy: Halozyme’s Subcutaneous Conversions Grow As Rivals Hope To Break In - Pink Sheet
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Sees Large Drop in Short Interest - MarketBeat
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer - Quantisnow
Acumen Pharmaceuticals Inc (ABOS) 財務データ
収益
当期純利益
現金流量
EPS
Acumen Pharmaceuticals Inc (ABOS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 19 '24 |
Sale |
3.48 |
8,933 |
31,048 |
108,867 |
| Zuga Matt | CFO & Chief Business Officer |
Jan 18 '24 |
Sale |
3.71 |
4,242 |
15,717 |
211,445 |
| Siemers Eric | Chief Medical Officer |
Jan 18 '24 |
Sale |
3.71 |
3,124 |
11,604 |
117,576 |
| Barton Russell | Chief Operating Officer |
Jan 18 '24 |
Sale |
3.73 |
2,833 |
10,555 |
96,867 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):